skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: SU-F-T-268: A Feasibility Study of Independent Dose Verification for Vero4DRT

Abstract

Purpose: Vero4DRT (Mitsubishi Heavy Industries Ltd.) has been released for a few years. The treatment planning system (TPS) of Vero4DRT is dedicated, so the measurement is the only method of dose verification. There have been no reports of independent dose verification using Clarksonbased algorithm for Vero4DRT. An independent dose verification software program of the general-purpose linac using a modified Clarkson-based algorithm was modified for Vero4DRT. In this study, we evaluated the accuracy of independent dose verification program and the feasibility of the secondary check for Vero4DRT. Methods: iPlan (Brainlab AG) was used as the TPS. PencilBeam Convolution was used for dose calculation algorithm of IMRT and X-ray Voxel Monte Carlo was used for the others. Simple MU Analysis (SMU, Triangle Products, Japan) was used as the independent dose verification software program in which CT-based dose calculation was performed using a modified Clarkson-based algorithm. In this study, 120 patients’ treatment plans were collected in our institute. The treatments were performed using the conventional irradiation for lung and prostate, SBRT for lung and Step and shoot IMRT for prostate. Comparison in dose between the TPS and the SMU was done and confidence limits (CLs, Mean ± 2SD %) were compared to thosemore » from the general-purpose linac. Results: As the results of the CLs, the conventional irradiation (lung, prostate), SBRT (lung) and IMRT (prostate) show 2.2 ± 3.5% (CL of the general-purpose linac: 2.4 ± 5.3%), 1.1 ± 1.7% (−0.3 ± 2.0%), 4.8 ± 3.7% (5.4 ± 5.3%) and −0.5 ± 2.5% (−0.1 ± 3.6%), respectively. The CLs for Vero4DRT show similar results to that for the general-purpose linac. Conclusion: The independent dose verification for the new linac is clinically available as a secondary check and we performed the check with the similar tolerance level of the general-purpose linac. This research is partially supported by Japan Agency for Medical Research and Development (AMED)« less

Authors:
;  [1];  [2];  [3];  [4];  [2]; ; ;  [4]; ;  [1];  [5]
  1. Kobe City Medical Center General Hospital, Kobe, Hyogo (Japan)
  2. (Japan)
  3. Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto, Tokyo (Japan)
  4. Institute of Biomedical Research and Innovation, Kobe, Hyogo (Japan)
  5. National Cancer Center, Kashiwa, Chiba (Japan)
Publication Date:
OSTI Identifier:
22648882
Resource Type:
Journal Article
Resource Relation:
Journal Name: Medical Physics; Journal Volume: 43; Journal Issue: 6; Other Information: (c) 2016 American Association of Physicists in Medicine; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; 61 RADIATION PROTECTION AND DOSIMETRY; ALGORITHMS; COMPUTER CODES; FEASIBILITY STUDIES; LINEAR ACCELERATORS; LUNGS; PROSTATE; RADIATION DOSES; RADIOTHERAPY; VERIFICATION; X RADIATION

Citation Formats

Yamashita, M, Kokubo, M, Institute of Biomedical Research and Innovation, Kobe, Hyogo, Takahashi, R, Takayama, K, Kobe City Medical Center General Hospital, Kobe, Hyogo, Tanabe, H, Sueoka, M, Okuuchi, N, Ishii, M, Iwamoto, Y, and Tachibana, H. SU-F-T-268: A Feasibility Study of Independent Dose Verification for Vero4DRT. United States: N. p., 2016. Web. doi:10.1118/1.4956408.
Yamashita, M, Kokubo, M, Institute of Biomedical Research and Innovation, Kobe, Hyogo, Takahashi, R, Takayama, K, Kobe City Medical Center General Hospital, Kobe, Hyogo, Tanabe, H, Sueoka, M, Okuuchi, N, Ishii, M, Iwamoto, Y, & Tachibana, H. SU-F-T-268: A Feasibility Study of Independent Dose Verification for Vero4DRT. United States. doi:10.1118/1.4956408.
Yamashita, M, Kokubo, M, Institute of Biomedical Research and Innovation, Kobe, Hyogo, Takahashi, R, Takayama, K, Kobe City Medical Center General Hospital, Kobe, Hyogo, Tanabe, H, Sueoka, M, Okuuchi, N, Ishii, M, Iwamoto, Y, and Tachibana, H. Wed . "SU-F-T-268: A Feasibility Study of Independent Dose Verification for Vero4DRT". United States. doi:10.1118/1.4956408.
@article{osti_22648882,
title = {SU-F-T-268: A Feasibility Study of Independent Dose Verification for Vero4DRT},
author = {Yamashita, M and Kokubo, M and Institute of Biomedical Research and Innovation, Kobe, Hyogo and Takahashi, R and Takayama, K and Kobe City Medical Center General Hospital, Kobe, Hyogo and Tanabe, H and Sueoka, M and Okuuchi, N and Ishii, M and Iwamoto, Y and Tachibana, H},
abstractNote = {Purpose: Vero4DRT (Mitsubishi Heavy Industries Ltd.) has been released for a few years. The treatment planning system (TPS) of Vero4DRT is dedicated, so the measurement is the only method of dose verification. There have been no reports of independent dose verification using Clarksonbased algorithm for Vero4DRT. An independent dose verification software program of the general-purpose linac using a modified Clarkson-based algorithm was modified for Vero4DRT. In this study, we evaluated the accuracy of independent dose verification program and the feasibility of the secondary check for Vero4DRT. Methods: iPlan (Brainlab AG) was used as the TPS. PencilBeam Convolution was used for dose calculation algorithm of IMRT and X-ray Voxel Monte Carlo was used for the others. Simple MU Analysis (SMU, Triangle Products, Japan) was used as the independent dose verification software program in which CT-based dose calculation was performed using a modified Clarkson-based algorithm. In this study, 120 patients’ treatment plans were collected in our institute. The treatments were performed using the conventional irradiation for lung and prostate, SBRT for lung and Step and shoot IMRT for prostate. Comparison in dose between the TPS and the SMU was done and confidence limits (CLs, Mean ± 2SD %) were compared to those from the general-purpose linac. Results: As the results of the CLs, the conventional irradiation (lung, prostate), SBRT (lung) and IMRT (prostate) show 2.2 ± 3.5% (CL of the general-purpose linac: 2.4 ± 5.3%), 1.1 ± 1.7% (−0.3 ± 2.0%), 4.8 ± 3.7% (5.4 ± 5.3%) and −0.5 ± 2.5% (−0.1 ± 3.6%), respectively. The CLs for Vero4DRT show similar results to that for the general-purpose linac. Conclusion: The independent dose verification for the new linac is clinically available as a secondary check and we performed the check with the similar tolerance level of the general-purpose linac. This research is partially supported by Japan Agency for Medical Research and Development (AMED)},
doi = {10.1118/1.4956408},
journal = {Medical Physics},
number = 6,
volume = 43,
place = {United States},
year = {Wed Jun 15 00:00:00 EDT 2016},
month = {Wed Jun 15 00:00:00 EDT 2016}
}